Form 990 for tax year 2024

Totals

Total revenue

$1,755,810

Total expenses

$1,651,386

Contributions and grants received

$1,558,455

Grants paid

$13,348

Program service revenue

$0

Investment income

$146,764

Other revenue

$50,591

Total assets, end of year

$4,009,793

Total liabilities, end of year

$411,086

Net assets or fund balances, end of year

$3,598,707

Program services expenses (Part IX)

$1,444,913

Management and general expenses

$144,140

Fundraising expenses

$62,333

Program service expenses (Part III)

$1,444,913

Program services were 87.5% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2024

• Some activities of the organization during 2024 include the following: LE&RN continued to expand programs to meet the goals of the expanded mission of fighting lymphatic disease through education, research, and advocacy. LE&RN continued the Global Patient Registry to stimulate research and support clinical trials and drug development. LE&RN continued its grant program, which allows young investigators to attend conferences focused on lymphatic research. LE&RN continued its educational and awareness outreach programs targeting academia, government, industry, and the medical and patient communities. LE&RN continued its monthly virtual symposium series, which brings the world's foremost authorities in lymphatic disease and lymphedema to patients, their families, and professionals. LE&RN updated its website and provided daily social media posts and monthly newsletters featuring significant events in the field. LE&RN produced six issues of Lymphatic Research and Biology, an international, peer-reviewedbiomedical journal providing a forum for the exchange of cutting-edge scientific developments in lymphatic science and medicine. LE&RN secured ongoing support from the Congressional and National Institutes of Health for lymphatic research. LE&RN continued the LE&RN/LymphNotes Lymphedema Scholarship Program to provide tuition support to therapists seeking certification in lymphedema therapy. LE&RN continued a web-based "Ask the Experts" feature that allows patients, their families, and professionals to ask the most prominent authorities in the field questions directly. LE&RN spokesperson and Academy Award Winner Kathy Bates appeared in print and television media to support research. LE&RN grew its Honorary Board, headed by Kathy Bates, and included notable celebrities who support LE&RN's mission. LE&RN's Virtual Expo was expanded to better serve patients and therapists. LE&RN and NAVBO prepared a biennial Virtual Lymphatic Forum for researchers LE&RN developed new chapters in several states and countries. LE&RN continued to lead global events related to its establishment of World Lymphedema Day on March 6, 2016. LE&RN advocates for lymphatic diseases to be a category eligible for research under the Department of Defense's Peer Review Medical Research Program. LE&RN supported and grew its Centers of Excellence in the Diagnosis & Treatment of Lymphatic Diseases to 70 member institutions. LE&RN, in collaboration with Stanford University, hosted the annual virtual State-of-the-Art Summit in Lymphatic Research & Medicine. LE&RN promoted its authored New York State bill, which mandates hospital institutions to provide lymphedema materials to all at-risk patients. LE&RN promoted its PSA video featuring National Spokesperson Kathy Bates, which was hosted on the Centers for Disease Control and Prevention (CDC) 's cancer-related websites. LE&RN continued its cancer-related lymphedema campaign, which was funded by a CDC Chronic Disease Awareness Grants program. LE&RN succeeded in having the Congressionally Directed Medical Research Program (CDMRP) include lymphedema as a category in the Department of Defense's Peer Reviewed Medical Research Program (PRMRP). LE&RN succeeded in making a request to Congress that the National Institutes of Health (NIH) establish a National Commission on Lymphatic Diseases. LE&RN established a global Patient Resource Center. LE&RN expanded and updated its Global Patient Registry. LE&RN created the CDC's first National Indicator Report on Cancer-Related lymphedema. LE&RN successfully advocated for a Program Manager in Lymphatics at the Advanced Research Agency for Health (ARPA-H) LE&RN, in concert with the research community, created a "Gaps in Lymphatic Research" document that was distributed to the NIH, CDC, ARPA-H, CDMRP, NNLBI, and NIAID.

  Expenses $1,444,913 · Grants $13,348 · Revenue $1,609,046

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

No itemized grants to organizations on this return.

Provenance

Return type

form_990

Tax year

2024

Filed

16 April 2025

IRS schema version

2024v5.1

Source object

202501069349301030

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.